FDA Declines Approval of Testosterone Drug for Third Time
August 2013
in “
The Lancet. Diabetes & endocrinology
”
Studysummary This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on thelancet.com →